Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
The present invention relates to a pharmaceutical composition for preventing and treating liver diseases, containing, as an active ingredient, cromolyn or a pharmaceutically acceptable salt thereof. Cromolyn inhibits the accumulation of collagen, which is known as a major secretion marker of hepatic stellate cells (HSCs), and the production of TGF-β, inhibits hepatocyte migration caused by the treatment of hepatocytes with TGF-β, inhibits an E-cadherin expression decrease caused by EMT progression, and has an anti-aging effect on hepatocytes, so as to have a dual effect of inhibiting the activity of HSCs and recovering the function of hepatocytes, thereby being usable as a fundamental therapeutic agent for various liver diseases including liver cirrhosis.
